Iovance Biotherapeutics (NASDAQ:IOVA) has seen a surge in options activity, with a notable split between bullish and bearish sentiments among high-rolling investors. The options trades, predominantly calls, target a price range of $7.5 to $30.0. Despite a current price drop of -3.61% to $16.8, professional analysts maintain positive ratings, with a consensus target price of $24.4. The company, a pioneer in T-cell therapy for solid tumor cancers, is preparing for potential U.S. regulatory approval and commercialization.